Current studies into retatrutide peptide highlight promising outlook for addressing weight and non-insulin dependent disease. The compound, a dual agonist of GLP-1 receptor and glucose-dependent insulinotropic polypeptide, seems to present enhanced body mass and blood sugar control in contrast to